Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4

Simple item page
dc.contributor.authorRobbins, S
dc.contributor.authorJackson, Ronald
dc.contributor.authorFenner, Frank
dc.contributor.authorBeaton, S
dc.contributor.authorMedveczky, C
dc.contributor.authorRamshaw, Ian
dc.contributor.authorRamsay, Alistair
dc.date.accessioned2015-12-13T22:53:40Z
dc.date.issued2005
dc.date.updated2015-12-11T10:58:36Z
dc.description.abstractImproved vaccines and therapies for virulent poxvirus infection are required, particularly in the light of recent threats of bioterrorism. Cidofovir (HPMPC) is an acyclic nucleoside analog with proven efficacy against poxviruses. Here, we evaluated HPMPC
dc.identifier.issn0166-3542
dc.identifier.urihttp://hdl.handle.net/1885/81914
dc.publisherElsevier
dc.sourceAntiviral Research
dc.subjectKeywords: cidofovir; interleukin 4; animal model; animal tissue; cellular immunity; controlled study; drug effect; drug efficacy; drug megadose; Ectromelia virus; lethality; mortality; mouse; nonhuman; Poxvirus infection; priority journal; review; single drug dose; Cidofovir; Immune suppression; Interleukin-4; Mousepox infection
dc.titleThe efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4
dc.typeJournal article
local.bibliographicCitation.issue1
local.bibliographicCitation.lastpage7
local.bibliographicCitation.startpage1
local.contributor.affiliationRobbins, S, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationJackson, Ronald, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationFenner, Frank, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationBeaton, S, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationMedveczky, C, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationRamshaw, Ian, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationRamsay, Alistair, College of Medicine, Biology and Environment, ANU
local.contributor.authoruidRobbins, S, u4012050
local.contributor.authoruidJackson, Ronald, u1576711
local.contributor.authoruidFenner, Frank, a114748
local.contributor.authoruidBeaton, S, u830309
local.contributor.authoruidMedveczky, C, u8104438
local.contributor.authoruidRamshaw, Ian, u8202754
local.contributor.authoruidRamsay, Alistair, v000863
local.description.embargo2037-12-31
local.description.notesImported from ARIES
local.description.refereedYes
local.identifier.absfor110799 - Immunology not elsewhere classified
local.identifier.ariespublicationMigratedxPub10222
local.identifier.citationvolume66
local.identifier.doi10.1016/j.antiviral.2004.12.003
local.identifier.scopusID2-s2.0-15244356314
local.type.statusPublished Version

Downloads

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
01_Robbins_The_efficacy_of_cidofovir_2005.pdf
Size:
143.41 KB
Format:
Adobe Portable Document Format
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2026 LYRASIS